DGAP-News: Glycotope secures one of the largest financing rounds in the European biotech sector

DGAP-News: Glycotope GmbH / Key word(s): Private Equity
Glycotope secures one of the largest financing rounds in the European
biotech sector

11.03.2014 / 11:52

---------------------------------------------------------------------

Glycotope secures one of the largest financing rounds in the European
biotech sector

Berlin, Germany, March 11, 2014 - Glycotope GmbH, a leading company in
glycobiology, has raised EUR 55 million in additional equity for the
development of its two most advanced new cancer drugs, PankoMab-GEX(TM) and
CetuGEX(TM), both in Phase IIb trials. The money will be used to complete
Phase IIb trials with several hundred patients in Europe and the United
States before the end of 2016. The Company's investors, which have now
provided total financing in excess of EUR 130 million, are Munich-based
Jossa Arznei GmbH (Strüngmann Group) and ELSA GmbH (Eckert Life Science
Accelerator) in Berlin.

In addition, Glycotope could secure the funding for final clinical
development of its improved fertility hormone, FSH-GEX(TM). The Phase III
clinical trials are expected to begin in summer 2014 and to involve roughly
1,000 female patients at international clinics in Europe and about the same
number in a further trial in the United States. If the studies confirm the
good results seen in the previous development phases, Glycotope could
achieve worldwide approval for FSH-GEX(TM) as early as 2017.

"We are extremely encouraged with the confidence shown by our investors and
by the fact that - thanks to these funding commitments - Glycotope is
becoming one of Germany's largest independent biotech companies," commented
Dr. Steffen Goletz, CEO and founder of Glycotope. "Our innovative
technologies for optimizing sugar structures on proteins, among other
things, enable us to increase the tolerability, effectiveness, and
affordability of a large number of proven medications."

About Glycotope

Glycotope specializes in the glycosylation of proteins and is one of
Germany's largest independent biotech companies. Founded in 2001 at the
Max-Delbrück-Center for Molecular Medicine in Berlin, it now has more than
180 employees at two locations in Berlin and Heidelberg. In addition to the
development projects described above, Glycotope has a broad portfolio of
other clinical candidates.

The new therapeutics at a glance

FSH-GEXTM is the first fully human glycosylated FSH (follicle-stimulating
hormone), recombinantly expressed in human cells and glycooptimized to
mimic endogenous human FSH for the treatment of women with fertility
problems. FSH-GEXTM has shown superior activity as well as excellent
tolerability in the Phase II study for Assisted Reproductive Technologies
when compared to the treatment with market leading Gonal-f(R). Phase III
clinical trials will start this year.

PankoMab-GEX(TM) is the first human glycosylated and glycooptimized
antibody against a novel tumor-specific carbohydrate-protein mixed epitope
(TA-MUC1) that is abundantly present on a larger set of tumor indications,
metastasis and cancer stem cells, while being virtually absent on normal
cells. In Phase I studies PankoMab-GEXTM showed excellent tolerability, no
significant toxicity and strong anti-tumor activity as a single agent in
various indications including ovarian and lung carcinoma. Last year a Phase
IIb clinical study of maintenance therapy for ovarian carcinoma was started
and first patients were treated with PankoMab-GEXTM.

CetuGEX(TM) is a novel anti-epidermal growth factor receptor (EGFR)
monoclonal antibody (mAb) with an optimized and human glycosylation for a
greatly enhanced anti-tumor activity and reduced side-effects as well as a
much broader patient and indication coverage. The Phase I study showed
strong and long term anti-tumor activity as single agent and a largely
improved side-effect profile. CetuGEX(TM) has successfully entered Phase
IIb clinical development.

TrasGEX(TM) is a novel glycooptimized anti-Her2 receptor (EGFR) monoclonal
antibody (mAb) with greatly enhanced anti-tumor activity and a much broader
coverage of patients and indications. The Phase I/IIa study has recently
been successfully completed affirming its strong, long term anti-tumor
activity.

All products were glycooptimized, fully human glycosylated and produced
with exceptional quality, reproducibility and yields using
GlycoExpress(TM). GlycoExpress(TM) (GEXTM) is the broadest, most potent and
validated glycooptimization and production technology for the improvement
of the vast majority of antibodies and protein biopharmaceuticals.

Contacts:

Glycotope GmbH
Dr. Franzpeter Bracht, COO
Robert-Roessle-Str. 10, D-13125 Berlin, Germany
Phone: +49-(0)30 94 89-2600
Fax: +49-(0)30 94 89-2609
Email: franzpeter.bracht@glycotope.com
Website: www.glycotope.com


End of Corporate News

---------------------------------------------------------------------

11.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


255701 11.03.2014